ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $2.16

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report)'s share price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.16 and traded as high as $2.20. ProQR Therapeutics shares last traded at $2.05, with a volume of 319,416 shares.

Analyst Upgrades and Downgrades

PRQR has been the subject of several recent analyst reports. Chardan Capital upped their target price on shares of ProQR Therapeutics from $2.00 to $2.50 and gave the company a "buy" rating in a research note on Thursday, March 14th. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, March 14th. Finally, StockNews.com downgraded ProQR Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, March 19th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $3.56.

ProQR Therapeutics Stock Performance

The stock has a fifty day moving average of $2.16 and a 200-day moving average of $1.86. The firm has a market capitalization of $162.71 million, a P/E ratio of -5.21 and a beta of 0.21. The company has a quick ratio of 3.54, a current ratio of 3.54 and a debt-to-equity ratio of 0.10.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last released its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). ProQR Therapeutics had a negative return on equity of 56.71% and a negative net margin of 431.65%. The firm had revenue of $3.54 million during the quarter, compared to the consensus estimate of $27.88 million. On average, research analysts anticipate that ProQR Therapeutics will post -0.37 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its position in shares of ProQR Therapeutics by 37.8% in the 1st quarter. JPMorgan Chase & Co. now owns 977,794 shares of the biopharmaceutical company's stock valued at $885,000 after acquiring an additional 268,315 shares during the period. BlackRock Inc. increased its position in ProQR Therapeutics by 8.1% during the first quarter. BlackRock Inc. now owns 527,396 shares of the biopharmaceutical company's stock worth $477,000 after buying an additional 39,482 shares during the last quarter. XTX Topco Ltd bought a new stake in ProQR Therapeutics in the first quarter valued at approximately $191,000. Renaissance Technologies LLC bought a new stake in ProQR Therapeutics in the first quarter valued at approximately $547,000. Finally, Virtu Financial LLC acquired a new stake in shares of ProQR Therapeutics in the second quarter valued at approximately $48,000. 32.65% of the stock is owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).